Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-10-19
2002-05-21
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06391876
ABSTRACT:
FIELD OF THE INVENTION
This invention describes new treatments for several nervous system disorders, including: Obsessive Compulsive Disorders, and panic Disorder. The treatment involves the administration of the drug reboxetine.
BACKGROUND
The introduction of tricyclic antidepressants in the early 1960s has provided a major advance in the treatment of neuropsychiatric disorders. Reactive and endogenous depressions, diagnoses formerly carrying grave prognostic implications, have become, with the introduction of the tricyclic, manageable disorders with a much smaller toll on the patient and the society as a whole.
The early tricyclic compounds were reuptake inhibitors of all the catecholamines released in the synaptic cleft, thus resulting in prolongation and enhancement of the dopamine (DA), noradrenaline (NA) and serotonin (5-hydroxytryptamine=5-HT) action. Lack of selectivity also causes undesired side effects particularly on the acetylcholine (especially the muscarinic component), and histamine mediated neurotransmission.
Because of these unwanted pharmacodynamic activities, cognitive impairment, sedation, urinary and gastrointestinal tract disturbances, increased intraocular pressure were limiting factors in the clinical use of these compounds and often required discontinuation of treatment. Of utmost concern were also the cardiac toxic effects and the proconvulsant activity of this group of drugs.
More recently, selective reuptake inhibitors for serotonin (SSRI) have been introduced with definite advantages in regard to fewer side effects without loss of efficacy.
Here we present the surprising finding that one particular drug from a new category of antidepressants, a so called noradrenaline (NA) reuptake inhibitor can be used to manage or treat a few special diseases, diseases having symptoms outside of what are usually considered depression symptoms.
REFERENCES:
patent: 4229449 (1980-10-01), Melloni et al.
patent: 5068433 (1991-11-01), Melloni et al.
patent: 5391735 (1995-02-01), Melloni et al.
patent: 29 01 032 (1979-08-01), None
patent: 35 40 093 (1986-05-01), None
patent: WO99/20279 (1999-04-01), None
“Depression and Anxiety: New Tools for Diagnosis and Treatment” J. Clin. Psychiatry—W. J. Katon (vol. 59, No. Suppl. 20, 1998, pp. 3-4 XP002113302.
“Noradrenergic Versus Serotonergic Antidepressants” Predictors of Treatment Response J. Clin. Psychiatry, A.F. Schatzberg, (vol. 59, No. Suppl. 14, 1998, pp. 15-18, XP002113303.
“The Place of Reboxetine in Antidepressant Therapy” J. Clin. Psychiatry, S.A. Montgomery, vol. 59, No. Suppl. 14, 1998, pp. 26-29, XP002113304.
“Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning” J. Psychopharmacol, A. Dubini, et al. vol. 11, No. 4 Suppl., 1997, pp. S17-S23 XP002113305.
“Reboxetine: a review of antidepressant tolerability” J. Psychopharmacol, M. Mucci—vol. 11, No. 4 Suppl, 1997, pp. S33-S37, XP002113306.
“Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes” H. Berzewski, et al., vol. 7, No. Suppl. 1, 1997, pp. S37-S47, XP002113307.
“Do noradrenaline and serotonin deffernetially affect social motivation and behaviour?” A. Dubini, et al., Eur. Neurophsychopharmacol., vol. 7, No. Suppl. 1, 1997, pp. S49-S55, XP002113308.
“Discussion” Eur. Neuropsychopharmacol, vol. 7, No. Suppl 1, 1997, pp. S71-S73, XP002113310 abstract.
“Does selectivity matter?” D.F.W. Deakin: Int. Clin. Psychopharmacol., vol. 11, No.: Suppl. 1, 1996, pp. 13-17, XP002113310.
B. E. Leonard,European Neuropsychopharmacology, 7 Suppl. 1, “Noradrenaline in Basic Models of Depression” pp. S11-S16; discussion S71-3 (1997).
J. Svestka,Cesk-Psychiatr, “Antidepressives of the 3rd, 4th, and 5thGeneration”, 90(1): 3-19 (1994).
RE Hales, et al,The American Psychiatric Press Textbook Psychiatry, Second Edition, “Anxiety Disorders”, (1994).
Dubini Adriana
Fong Wong Erik Ho
McCall John Michael
Taylor Duncan Paul
Von Voigtlander Philip F.
Jarvis William R. A.
Nesbitt Stephen L.
Pharmacia and Upjohn Company
Solomon Andrew M.
Wootton Thomas A.
LandOfFree
Reboxetine for treatment obsessive compulsive disorders and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reboxetine for treatment obsessive compulsive disorders and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reboxetine for treatment obsessive compulsive disorders and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2818523